Tuesday, 28 April 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 28 April 2026
News

PBAC pushes biologics to first line

Posted 28 April 2026 AM

The PBAC has given the thumbs up to a submission by the Department of Health to move AbbVie's Humira and various brands of infliximab, the active ingredient in J&J's Remicade, to the first line for paediatric patients with severe, and moderate to severe Crohn disease respectively. The prior therapy requirements for paediatric patients with Crohn's disease and ulcerative colitis remain.

This comes after lobbying from patient groups, including repeated questioning of the Department by Independent Senator for the ACT, David Pocock, during Senate Estimates. While the cost of Humira and infliximab are higher than standard medicines, the PBAC advised that the proposed first-line treatment would be cost effective at the current price.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.